AI Article Synopsis

  • The study aimed to evaluate the impact of subclinical thyroid disease on quality of life and cardiovascular risk in women.
  • A total of 1423 community-dwelling women aged 18-75 were analyzed by measuring thyroid hormone levels, well-being scores, and cardiovascular risk markers.
  • Results showed no significant differences in health-related quality of life or cardiovascular risk markers between women with subclinical hypothyroidism or hyperthyroidism and age-matched controls.

Article Abstract

Objectives: The aim of this study was to evaluate whether subclinical thyroid disease is associated with impaired health-related quality of life and a more adverse cardiovascular disease risk profile.

Design: A community-based cross-sectional study.

Setting And Participants: A total of 1423 non-healthcare-seeking women, aged 18-75 years were randomly recruited from the community via the electoral roll from April 2002 to August 2003.

Main Outcome Measures: These were the scores for the Short-Form 36 (SF-36), the Psychological General Well-being Index (PGWI), thyroid hormone levels, serum lipids and high sensitivity C-reactive protein (hsCRP). Subclinical hypothyroidism (SCH) and subclinical hyperthyroidism (SCHyper) were defined as serum TSH > 4.0 mIU/l and < 0.5 mIU/l, respectively, with a normal free thyroxine (free T4) level.

Results: Evaluable data were available for all participants. 10.7% of all women had an abnormal TSH value. The prevalence of a low TSH level by age group ranged from 1.2% to 6.4%, whereas the prevalence of an elevated TSH level ranged from 2.8% to 9.2% and increased with age (P = 0.002). There were no significant differences between women with SCH or SCHyper and age-matched controls for the total PGWI score or the Mental and Physical Component Scores of the SF-36. Women with SCH were no different from controls for serum lipids or hsCRP. Using linear regression, SCH vs. euthyroidism did not make an independent contribution to variation in either total cholesterol or triglycerides, with or without adjustment for age +/- age(2) +/- BMI.

Conclusions: Our data indicate that subclinical thyroid disease in women in the community is not associated with lower well-being or impaired health-related quality of life and SCH is not associated with increased serum markers of CVD risk.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2265.2007.02771.xDOI Listing

Publication Analysis

Top Keywords

health-related quality
12
quality life
12
subclinical thyroid
12
thyroid disease
12
cardiovascular disease
8
disease risk
8
impaired health-related
8
serum lipids
8
tsh level
8
women sch
8

Similar Publications

: Despite its estimated high prevalence among women and increasing awareness, lipedema remains under-investigated. Ignoring its debilitating nature, surgical treatment for this condition is frequently covered by health insurance only in advanced stages and after the exhaustion of conservative therapies. : A total of 1015 patients with lipedema were recruited via social media platforms.

View Article and Find Full Text PDF

Health-Related Quality of Life in Juvenile Idiopathic Arthritis: A Systematic Review of Phase III Clinical Trials.

J Clin Med

January 2025

Department of Clinical and Biological Sciences, Section of Translational Pharmacology, University of Turin, Regione Gonzole 10, 10043 Orbassano, Italy.

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, leading to severe disability and negatively affecting patients' health-related quality of life (HRQoL). The aim of this systematic review was to evaluate the adoption, reporting and assessment methodology of HRQoL in phase III clinical trials involving children with JIA. An electronic and manual search was conducted to identify primary and secondary publications of pharmacological trials conducted between 2012 and 2023.

View Article and Find Full Text PDF

: Multicomponent, non-pharmacological therapies are the preferred first-line treatments for fibromyalgia (FM), but little is known about them in primary care settings. Our study assessed the effectiveness of the FIBROCARE Program in improving the quality of life, functional impact, mood, and pain of people with FM. : We conducted a pragmatic, randomized controlled trial that was not blinded for both patients and the professionals delivering the treatments in the study groups.

View Article and Find Full Text PDF

The HRQ-6D is a newly developed instrument to measure Health-related quality of life (HRQOL) and EQ-5D is the gold standard for measuring HRQOL. This study aims to test the concurrent validity between EQ-5D and HRQ-6D measures among patients with different primary diagnoses. : This cross-sectional study uses two HRQOL measurement instruments, EQ-5D-3L and HRQ-6D.

View Article and Find Full Text PDF

Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae, and health-related quality of life (HRQoL) of this treatment are limited, this retrospective analysis aimed to explore these.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!